Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Pharmacogenomics of cetuximab in metastatic colorectal carcinoma

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
اقرأ أكثر حفظ في قائمتي
  • معلومة اضافية
    • Contributors:
      Silvestris, Nicola*; Vincenzi, Bruno; Brunetti, Anna Elisabetta; Loupakis, Fotiou; Dell'Aquila, Emanuela; Russo, Antonio; Scartozzi, Mario; Giampieri, Riccardo; Cascinu, Stefano; Lorusso, Vito; Tonini, Giuseppe; Falcone, Alfredo; Santini, Daniele
    • بيانات النشر:
      Future Medicine Ltd.
    • الموضوع:
      2014
    • Collection:
      IRIS Università degli Studi di Palermo
    • نبذة مختصرة :
      Cetuximab is a chimeric monoclonal antibody that has revolutionized the treatment of metastatic colorectal cancer. Knowledge of the mechanisms that underlie its effectiveness, as well as the primary and secondary resistance mechanisms, have led to important developments in the understanding of cetuximab biology. In light of knowledge gained from recent trials, the efficacy of cetuximab has been clearly demonstrated to depend upon RAS mutational status, moreover cetuximab should only be used in a subset of patients who may benefit. In this article, we critically review clinical and pharmacogenetic issues of cetuximab, focusing on the cost-effectiveness involved with the use of the drug.
    • Relation:
      info:eu-repo/semantics/altIdentifier/pmid/25410895; info:eu-repo/semantics/altIdentifier/wos/WOS:000345342300007; volume:15; issue:13; firstpage:1701; lastpage:1715; numberofpages:15; journal:PHARMACOGENOMICS; http://hdl.handle.net/10447/295558; http://www.futuremedicine.com/loi/pgs?cookieSet=1
    • الرقم المعرف:
      10.2217/pgs.14.124
    • الدخول الالكتروني :
      http://hdl.handle.net/10447/295558
      https://doi.org/10.2217/pgs.14.124
      http://www.futuremedicine.com/loi/pgs?cookieSet=1
    • Rights:
      info:eu-repo/semantics/openAccess
    • الرقم المعرف:
      edsbas.DE39471E